De Baets Frans, Schelstraete Petra, Van Daele Sabine, Haerynck Filomeen, Vaneechoutte Mario
Cystic Fibrosis Centre, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium.
J Cyst Fibros. 2007 Jan;6(1):75-8. doi: 10.1016/j.jcf.2006.05.011. Epub 2006 Jun 21.
Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few published data on the clinical impact of this infection or chronic colonisation.
Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the moment of the first positive culture and during the period of colonisation were compared to age (+/-1 year), gender and to Pseudomonas aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures.
The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of our definition of colonisation. Colonised patients had a median age of 20 years (range 11-27 years) and a mean colonisation period of 1.5 (+/-0.9) years. At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11+/-3 versus 16+/-3, p<0.002), lower Brasfield chest X-ray scores (14+/-3 versus 18+/-3, p<0.019), lower FVC values (70%+/-22 versus 94%+/-12, p<0.017) and lower FEV(1) values (55%+/-32 versus 78%+/-23, p=0.123), although the latter did not reach significance. There was no significant difference in body mass index (BMI) (18.7+/-3 kg/m2 versus 19.6+/-3 kg/m2, p=0.8). Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5, p<0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: -6.25+/-12.34% versus -5.62+/-8.30%, p 0.77, FEV1: -5.62+/-8.30% versus -1.87+/-11.58%, p<0.47).
The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older, with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment courses, no faster decline in lung function was observed in A. xylosoxidans positive patients.
木糖氧化无色杆菌越来越多地从囊性纤维化(CF)患者的痰液中培养出来;然而,关于这种感染或慢性定植的临床影响,发表的数据很少。
依靠DNA指纹技术,我们研究了木糖氧化无色杆菌在我们CF人群中的流行情况。在一项回顾性病例对照研究中,将至少9个月内有至少3次木糖氧化无色杆菌痰培养阳性的患者在首次阳性培养时以及定植期间的临床状况,与年龄(±1岁)、性别相匹配,且从未有过木糖氧化无色杆菌阳性痰培养的铜绿假单胞菌定植的CF患者进行比较。
至少有一次木糖氧化无色杆菌培养阳性的患者患病率为17.9%。5.3%的患者符合我们定植定义的标准。定植患者的中位年龄为20岁(范围11 - 27岁),平均定植期为1.5(±0.9)年。在首次阳性培养时,我们发现肺部HRCT扫描的Bhalla评分显著更低(11±3对16±3,p<0.002),Brasfield胸部X线评分更低(14±3对18±3,p<0.019),FVC值更低(70%±22对94%±12,p<0.017)以及FEV(1)值更低(55%±32对78%±23,p = 0.123),尽管后者未达到显著差异。体重指数(BMI)无显著差异(18.7±3 kg/m2对19.6±3 kg/m2,p = 0.8)。在研究期间,木糖氧化无色杆菌定植的患者确实更需要静脉抗生素治疗疗程(19次对5次,p<0.001);然而,在研究期间肺功能下降无显著差异(FVC:-6.25±12.34%对-5.62±8.30%,p = 0.77,FEV1:-5.62±8.30%对-1.87±11.58%,p<0.47)。
木糖氧化无色杆菌感染或定植的患病率可能被低估。定植患者大多年龄较大,肺部损伤更明显,肺功能值更低。尽管更需要静脉抗生素治疗疗程,但木糖氧化无色杆菌阳性患者未观察到更快的肺功能下降。